We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The company posted adjusted earnings per share (EPS) of $2.49 in the last reported quarter, which missed the Zacks Consensus Estimate by 3.11%. Align Technology beat on earnings in three of the trailing four quarters, and missed in one, the average surprise being 1.65%.
ALGN’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $971.5 million, which suggests a decline of 0.7% from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.37 per share, which implies a 0.9% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged at $2.37 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Factors at Play
Clear Aligner Business
Similar to the last reported quarter, Align Technology is likely to have witnessed strength in Clear Aligner volumes, reflecting growth across regions, especially APAC and EMEA. Growth in the APAC and EMEA regions is likely to have been driven the orthodontic and GP dentist channels across teens, kids and adult patients. Meanwhile, from a product standpoint, Invisalign First is expected to be key year-over-year growth driver across all regions. Additionally, the Invisalign Palate Expander system might contribute to year-over-year growth in North America in the third quarter.
During the third quarter, Align Technology’s Invisalign System with mandibular advancement featuring occlusal blocks was commercially launched in India and Malaysia. It is designed to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. Additionally, the company’s Invisalign Palatal Expander System has been notified as Class B medical device in India and Malaysia, with commercial availability in both locations. These factors, too, are likely to have aided Align Technology’s third-quarter revenues.
The Systems & Services business is projected to have witnessed growth in the third quarter due to increased scanner volumes and non-system revenues driven by iTero Lumina wand upgrades. The continuous uptake of the iTero Lumina Scanner with ortho workflow and positive response from customers are likely to have boosted the company’s revenues.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, that is not the case here, as you can see below:
Earnings ESP: Align Technologies has an Earnings ESP of -1.62%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +32.65% and a Zacks Rank #1 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter's figure.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. Per the Zacks Consensus Estimate, ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
IDXX’s earnings topped estimates in each of the trailing four quarters, the average surprise being 6.08%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 12.1% from the year-ago quarter figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Key Takeaways
Align Technology, Inc. (ALGN - Free Report) is set to release third-quarter 2025 results on Oct. 29, after the closing bell.
The company posted adjusted earnings per share (EPS) of $2.49 in the last reported quarter, which missed the Zacks Consensus Estimate by 3.11%. Align Technology beat on earnings in three of the trailing four quarters, and missed in one, the average surprise being 1.65%.
ALGN’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $971.5 million, which suggests a decline of 0.7% from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.37 per share, which implies a 0.9% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged at $2.37 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Factors at Play
Clear Aligner Business
Similar to the last reported quarter, Align Technology is likely to have witnessed strength in Clear Aligner volumes, reflecting growth across regions, especially APAC and EMEA. Growth in the APAC and EMEA regions is likely to have been driven the orthodontic and GP dentist channels across teens, kids and adult patients. Meanwhile, from a product standpoint, Invisalign First is expected to be key year-over-year growth driver across all regions. Additionally, the Invisalign Palate Expander system might contribute to year-over-year growth in North America in the third quarter.
During the third quarter, Align Technology’s Invisalign System with mandibular advancement featuring occlusal blocks was commercially launched in India and Malaysia. It is designed to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. Additionally, the company’s Invisalign Palatal Expander System has been notified as Class B medical device in India and Malaysia, with commercial availability in both locations. These factors, too, are likely to have aided Align Technology’s third-quarter revenues.
Align Technology, Inc. Price and EPS Surprise
Align Technology, Inc. price-eps-surprise | Align Technology, Inc. Quote
Imaging Systems & CAD/CAM Service Business
The Systems & Services business is projected to have witnessed growth in the third quarter due to increased scanner volumes and non-system revenues driven by iTero Lumina wand upgrades. The continuous uptake of the iTero Lumina Scanner with ortho workflow and positive response from customers are likely to have boosted the company’s revenues.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, that is not the case here, as you can see below:
Earnings ESP: Align Technologies has an Earnings ESP of -1.62%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +32.65% and a Zacks Rank #1 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter's figure.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. Per the Zacks Consensus Estimate, ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
IDXX’s earnings topped estimates in each of the trailing four quarters, the average surprise being 6.08%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 12.1% from the year-ago quarter figure.